5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 401–500 of 1,028
DNA repair in the trinucleotide repeat disorders
Jones, L., Houlden, H., & Tabrizi, S. J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30350-7 · Cited by 106
Si-doped phagraphene as a drug carrier for adrucil anti-cancer drug: DFT studies
Bagheri, R., Babazadeh, M., Vessally, E., Es’haghi, M., & Bekhradnia, A. (2018) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2018.01.020 · Cited by 99
Büchel, B., Rhyn, P., Schürch, S., Bühr, C., Amstutz, U., & Largiadèr, C. R. (2012) · Biomedical Chromatography · doi:10.1002/bmc.2741 · Cited by 99
“Over 50 years after its introduction into clinical practice, chemotherapy using the anti-metabolite 5-fluorouracil (5-FU) is still of great clinical relevance (Heidelberger et al., 1957; Longley et al., 2003; Meyerhardt and Mayer, 2005).”
BackgroundmiR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1
Liu, H., Yin, Y., Hu, Y., Feng, Y., Bian, Z., Yao, S., Li, M., You, Q., & Huang, Z. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.04.011 · Cited by 101
Tong, J., Xie, G., He, J., Li, J., Pan, F., & Liang, H. (2011) · BioMed Research International · doi:10.1155/2011/740564 · Cited by 103
“5-FU is a chemotherapy drug used to treat several types of cancer, including colorectal, breast, esophageal, and stomach [15].”
BackgroundAnticancer drug-layered hydroxide nanohybrids as potent cancer chemotherapy agents
Choi, S., Oh, J., & Choy, J. (2007) · Journal of Physics and Chemistry of Solids · doi:10.1016/j.jpcs.2007.10.140 · Cited by 98
Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells
Untereiner, A. A., Pavlidou, A., Druzhyna, N., Papapetropoulos, A., Hellmich, M. R., & Szabó, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.007 · Cited by 101
An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Rawat, D., Shrivastava, S., Naik, R. A., Chhonker, S. K., Mehrotra, A., & Koiri, R. K. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180604085612 · Cited by 107
Zhao, Y., Das, S. C., Sekine, T., Mabuchi, H., Irie, T., Sakai, J., Wen, D., Zhu, W., Ben, T., & Negishi, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300172 · Cited by 98
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections
Sauna, Z. E., Shukla, S., & Ambudkar, S. V. (2005) · Molecular BioSystems · doi:10.1039/b504392a · Cited by 98
Showalter, S. L., Showalter, T. N., Witkiewicz, A., Havens, R., Kennedy, E. P., Hucl, T., Kern, S. E., Yeo, C. J., & Brody, J. R. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.7.6181 · Cited by 98
“We will discuss the literature regarding TS and 5-FU and consider the logical questions: (1) Should we move forward beyond reiterating the often published trend of TS expression and 5-FU response to consider other markers or targets of 5-FU? (2) Should TS be considered with additional predictive markers such as 5-FU m…”
BackgroundClinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Moore, A. Y. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630902789326 · Cited by 98
Shojaeı, A. F., Tabatabaeian, K., Shakeri, S., & Karimi, F. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.02.082 · Cited by 97
Sun, G., Li, Z., He, Z., Wang, W., Wang, S., Zhang, X., Cao, J., Xu, P., Wang, H., Huang, X., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01758-w · Cited by 98
Heffeter, P., Jakupec, M. A., Körner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B. K., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.002 · Cited by 97
“Lack of acquired resistance development to KP772 seems not to be a general consequence of collateral sensitivity as there exist several reports on cell models resistant against other hyperactive drugs like 5-FU, gemcitabine, and VP [26,37,38].”
BackgroundLee, S., & Oh, M. (2015) · Metabolic Engineering · doi:10.1016/j.ymben.2015.01.004 · Cited by 101
“…suicidal because the dysfunction of RNA by the uracil analog, fluorouracil, is toxic to both prokaryotic (Horowitz and Chargaff, 1959; Morris, 1993; Ramberg et al., 1978) and eukaryotic systems (Heidelberger and Ansfield, 1963; Heidelberger et al., 1983; Longley et al., 2003; Sikdar and Kim, 2010).”
BackgroundInfluentialFOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
Mohelníková-Duchoňová, B., Melichar, B., & Soucek, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i30.10316 · Cited by 116
Optimally discriminative subnetwork markers predict response to chemotherapy
Dao, P., Wang, K., Collins, C. C., Ester, M., Lapuk, A. V., & Şahinalp, S. C. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr245 · Cited by 109
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G., Kienhuis, E., Creemers, G., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.010 · Cited by 96
Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors
Young, O., Ngo, N. T., Lin, L., Stanbery, L., Creeden, J. F., Hamouda, D., & Nemunaitis, J. J. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100917 · Cited by 101
Advances and clinical challenges of mesenchymal stem cell therapy
Mei, R., Wan, Z., Yang, C., Shen, X., Wang, R., Zhang, H., Yang, R., Li, J., Song, Y., & Su, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1421854 · Cited by 102
Amorim, R., Pinheiro, C. M., Miranda‐Gonçalves, V., Pereira, H., Moyer, M. P., Preto, A., & Baltazar, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.015 · Cited by 101
5-Fluorouracil affects assembly of stress granules based on RNA incorporation
Kaehler, C., Isensee, J., Hucho, T. B., Lehrach, H., & Krobitsch, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku264 · Cited by 111
“As illustrated in Figure 6A, after cellular uptake 5-FU is converted into the metabolites FUrd and FdUrd that are further metabolized to FUTP and FdUTP, respectively (1).”
BackgroundInfluentialGenetic modification of stem cells for transplantation
Phillips, M. I., & Tang, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.035 · Cited by 101
“CD is an enzyme that converts far less toxic substrate 5-fluorocytosine (5-FC) to 5FU and the toxic metabolites production [102].”
BackgroundRecent studies of 5-fluorouracil resistance in pancreatic cancer
Wang, W., Yang, Y., Zhao, Y.-P., Zhang, T.-P., Liao, Q., & Shu, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15682 · Cited by 109
Oral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
The Complex Mechanism of Antimycobacterial Action of 5-Fluorouracil
Singh, V., Brecik, M., Mukherjee, R., Evans, J. C., Svetlíková, Z., Blaško, J., Surade, S. B., Blackburn, J. M., Warner, D. F., Mikušová, K., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.11.006 · Cited by 97
“…treatment (Showalter et al., 2008), which pointed toward the potential importance of alternate metabolites and targets for 5-FU, such as FUTP and RNA misincorporation (Longley et al., 2003), and underscored the need for more predictive biomarkers of therapeutic response to this drug (Bunz, 2008).”
BackgroundHaag, C., Stadel, D., Zhou, S., Bachem, M. G., Möller, P., Debatin, K., & Fulda, S. (2010) · Gut · doi:10.1136/gut.2009.202325 · Cited by 101
“5-Fluorouracil (5-FU)-mediated downregulation of c-FLIP sensitises pancreatic carcinoma cells for death receptorinduced apoptosis In an alternative approach to target c-FLIP, we used the chemotherapeutic drug 5-FU, an analogue of uracil whose active metabolites inhibit RNA synthesis.(40) Interestingly, 5-FU caused a c…”
BackgroundMethodInfluential5-Fluorouracil Enhances Exosome-Dependent Accumulation of Polyadenylated rRNAs
Fang, F., Hoskins, J., & Butler, J. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10766-10776.2004 · Cited by 93
“5-Fluorouracil (5FU) is one of the most successful and widely used chemotherapeutics for the treatment of solid tumors in cancer patients (27).”
BackgroundThe role of melatonin on chemotherapy-induced reproductive toxicity
Haghi‐Aminjan, H., Asghari, M. H., Farhood, B., Rahimifard, M., Goradel, N. H., & Abdollahi, M. R. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12855 · Cited by 99
“5-fluorouracil (5-FU) is an antimetabolite chemotropic drug acts through two mechanisms including interfering with DNA and RNA that results in production of macromolecules as well as inhibiting essential biosynthetic functions.([58]) 5-FU is widely used in the treatment of cancers, including breast, colorectal, head a…”
BackgroundFluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management
Layoun, M. E., Wickramasinghe, C. D., Peralta, M. V., & Yang, E. H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0521-1 · Cited by 94
Henricks, L. M., Opdam, F. L., Beijnen, J. H., Cats, A., & Schellens, J. H. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx411 · Cited by 93
“Only a small fraction of 5-FU (1%–5%) is converted intracellularly into the cytotoxic metabolites fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP; Figure 1) [9, 10].”
BackgroundStress granule: A promising target for cancer treatment
Gao, X., Jiang, L., Gong, Y., Chen, X., Ying, M., Zhu, H., He, Q., Yang, B., & Cao, J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14790 · Cited by 99
He, J., Xie, G., Tong, J., Peng, Y., Haihui, H., Li, J., Wang, N., & Liang, H. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0062-x · Cited by 99
“5-Fluorouracil (5-FU) is the most commonly used drug in colon cancer therapy with the capability to induce apoptosis in normal and tumor intestinal cells [1].”
Liver metastases from colorectal cancer: radioembolization with systemic therapy
Nicolay, N. H., Berry, D. P., & Sharma, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.165 · Cited by 97
Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression
Wang, W., Guo, W., Li, L., Fu, Z., Liu, W., Gao, J., Shu, Y., Xu, Q., Sun, Y., & Gu, Y. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.024 · Cited by 91
Oxo−Hydroxy Tautomerism of 5-Fluorouracil: Water-Assisted Proton Transfer
Markova, N. V., Enchev, V. G., & Timtcheva, I. (2005) · The Journal of Physical Chemistry A · doi:10.1021/jp046132m · Cited by 98
Novel hydrogel microspheres of chitosan and pluronic F-127 for controlled release of 5-fluorouracil
Rokhade, A. P., Shelke, N. B., Patil, S. A., & Aminabhavi, T. M. (2007) · Journal of Microencapsulation · doi:10.1080/02652040701281365 · Cited by 93
“To achieve good therapeutic effects, the concentration of 5-FU should be kept at low level and is to be sustained released (Longley et al. 2003).”
BackgroundRoudier, E., Mistafa, O., & Stenius, U. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0352 · Cited by 92
Berkowitz, D. B., Karukurichi, K. R., de la Salud‐Bea, R., Nelson, D. L., & McCune, C. D. (2008) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2008.05.016 · Cited by 92
Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors
Yssel, A., Vanderleyden, J., & Steenackers, H. P. L. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx151 · Cited by 95
The effect of microneedles on the skin permeability and antitumor activity of topical 5-fluorouracil
Naguib, Y. W., Kumar, A., & Cui, Z. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.013 · Cited by 91
Zhao, K., Cheng, X., Ye, Z., Li, Y., Peng, W., Wu, Y., & Xing, C. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00517-20 · Cited by 96
“through inducing RNA and DNA double-strand breakage (5, 26).”
BackgroundJustino, P. F. C., Melo, L. F. M., Nogueira, A. F., Morais, C. M., Mendes, W. D. O., Franco, Á. X., de Souza, E. P., Ribeiro, R. A., de Souza, M. H. L. P., & Soares, P. M. G. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2663-x · Cited by 91
“5-Fluorouracil (5-FU), widely used as chemotherapeutic for colorectal and breast cancer [10, 11], is known to induce intestinal damage through IM [12] and stem cell apoptosis [13].”
BackgroundEvidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast
Gustavsson, M., & Ronne, H. (2008) · RNA · doi:10.1261/rna.966208 · Cited by 92
Franklin, D. A., He, Y., Leslie, P. L., Tikunov, A. P., Fenger, N., Macdonald, J. M., & Zhang, Y. (2016) · Scientific Reports · doi:10.1038/srep38067 · Cited by 90
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
Detection of Reactive Oxygen Species by a Carbon-Dot–Ascorbic Acid Hydrogel
Bhattacharya, S., Sarkar, R., Nandi, S., Porgador, A., & Jelinek, R. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03749 · Cited by 89
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Chen, Y., & Zhang, Y. (2018) · Advanced Science · doi:10.1002/advs.201700964 · Cited by 99
Afrin, S., Giampieri, F., Forbes-Hernández, T. Y., Gasparrini, M., Amici, A., Cianciosi, D., Quiles, J. L., & Battino, M. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.07.014 · Cited by 92
A novel core-shell nanofiber drug delivery system intended for the synergistic treatment of melanoma
Zhu, L.-F., Zheng, Y., Fan, J., Yao, Y., Ahmad, Z., & Chang, M. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105002 · Cited by 92
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
Glimelius, B. L. G., Stintzing, S., Marshall, J. L., Yoshino, T., & de Gramont, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102218 · Cited by 112
Koopman, M., Venderbosch, S., Nagtegaal, I. D., van Krieken, J. H., & Punt, C. J. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.023 · Cited by 98
Hatamluyi, B., Es’haghi, Z., Zahed, F. M., & Darroudi, M. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.02.017 · Cited by 89
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Wigle, T. J., Tsvetkova, E. V., Welch, S. A., & Kim, R. B. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050199 · Cited by 100
“The combination of RNA damage, DNA damage, and inhibition of cell cycle provide the mechanistic basis for the antineoplastic effects of fluoropyrimidines (Figure 1, for review see [11]).”
BackgroundThe emerging role of noncoding RNAs in colorectal cancer chemoresistance
Wei, L., Wang, X., Lv, L., Zheng, Y., Zhang, N., & Yang, M. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00466-8 · Cited by 91
Kaymak, I., Maier, C. R., Schmitz, W., Campbell, A. D., Dankworth, B., Ade, C. P., Walz, S., Paauwe, M., Kalogirou, C., Marouf, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0650 · Cited by 89
Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: A review
Shirani, K., Yousefsani, B. S., Shirani, M., & Karimi, G. (2020) · Phytotherapy Research · doi:10.1002/ptr.6641 · Cited by 95
Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy
Ramirez, J. A. Z., Romagnoli, G. G., & Kaneno, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118745 · Cited by 95
Chitosan modified metal–organic frameworks as a promising carrier for oral drug delivery
Li, L., Han, S., Zhao, S., Li, X., Liu, B., & Liu, Y. (2020) · RSC Advances · doi:10.1039/d0ra08459j · Cited by 88
Transgene-free Genome Editing in Plants
Gu, X., Liu, L., & Zhang, H. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.805317 · Cited by 94
“FCY converts nontoxic 5fluorocytosine (5-FC) into the toxic antipyrimidine 5fluorouracil (5-FU), which blocks thymidine synthetic processes and is incorporated into DNA and RNA (Mullen et al., 1992; Longley et al., 2003).”
BackgroundBiomedical Applications of Metal–Organic Frameworks Revisited
Sezgin, P., Gulcay-Ozcan, E., Vučkovski, M., Bondžić, A. M., Eruçar, İ., & Keskın, S. (2025) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.4c03698 · Cited by 128
Regulation and Functional Contribution of Thymidine Kinase 1 in Repair of DNA Damage
Chen, Y., Eriksson, S., & Chang, Z.-F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137042 · Cited by 111
A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation
Xiao, Z., Xue, J., Sowin, T. J., Rosenberg, S. H., & Zhang, H. (2004) · Oncogene · doi:10.1038/sj.onc.1208309 · Cited by 103
“In addition, two other active metabolites of 5-FU, FUTP and FdUTP, compete with normal pool of nucleotides and incorporate into RNA or DNA to compromise the normal functions of these macromolecules (Longley et al., 2003; Sampath et al., 2003).”
BackgroundLI, X., ZHAO, H., ZHOU, X., & SONG, L. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2726 · Cited by 86
“5-Fluorouracil (5-FU) is a commonly-used chemotherapeutic agent that is effective for treating a range of malignant tumors (6).”
BackgroundPaxton, J. W. (2012) · InTech eBooks · doi:10.5772/1180 · Cited by 96
Buzzelli, J. N., Ouaret, D., Brown, G., Allen, P. D., & Muschel, R. J. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.01.016 · Cited by 86
“Such drugs predominately target proliferating cells (Ehrsson et al., 2002; Longley et al., 2003), therefore it is not surprising that the significant growth delay in CRC liver metastases organoids observed following multiple rounds of chemotherapy permits chemotherapy evasion.”
BackgroundTherapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance
Maroufi, N. F., Rashidi, M., Vahedian, V., Akbarzadeh, M., Fattahi, A., & Nouri, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117106 · Cited by 92
Advances and perspectives in phototherapy-based combination therapy for cancer treatment
Yi, J., Liu, L., Gao, W., Zeng, J., Chen, Y., Pang, E.-N., Lan, M., & Yu, C. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00483c · Cited by 94
Xiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12579 · Cited by 96
“…[313] and mitoxantrone [314]), taxanes (paclitaxel and docetaxel) [315], gemcitabine [316], cyclophosphamide [317], bortezomib [318], 5-fluorouracil [319], the third-generation platinum analog oxaliplatin [241], curcumin [320], cardiac glycosides [321] and the alkylating agent melphalan [322].”
BackgroundLam, T. L., Wong, G., Chong, H.-C., Cheng, P. N.-M., Choi, S. C., Chow, T. L., Kwok, S.-Y., Poon, R. T. P., Wheatley, D. N., Lo, W., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.031 · Cited by 93
“5FU is an antimetabolite that exerts its anti-cancer effects through inhibition of thymidylate synthase and the incorporation of its metabolites into RNA and DNA, thus preventing DNA synthesis and inhibiting cell cycle progression [48,49].”
BackgroundKang, N.-H., Hwang, K.-A., Kim, S. U., Kim, Y.-B., Hyun, S., Jeung, E.-B., & Choi, K.-C. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.30 · Cited by 94
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 97
Cruz-Muñiz, M. Y., López-Jácome, L. E., Hernández-Durán, M., Franco‐Cendejas, R., Licona-Limón, P., Ramos-Balderas, J. L., Martínez‐Vázquez, M., Belmont-Díaz, J., Wood, T. K., & García‐Contreras, R. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.08.022 · Cited by 87
“In fact, several anticancer drugs have important antibacterial properties [1], among them the antimetabolite 5-fluorouracil (5-FU) that is currently used for the treatment of several kinds of cancers, including colorectal, oesophageal, breast, pancreatic and skin cancers [3].”
BackgroundNagata, M., Nakayama, H., Tanaka, T., Yoshida, R., Yoshitake, Y., Fukuma, D., Kawahara, K., Nakagawa, Y., Ota, K., Hiraki, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.387 · Cited by 90
“As TS and TP are already well known to be involved in 5-FU resistance in many malignancies (Metzger et al, 1998; Kawano et al, 2003; Longley et al, 2003), we focussed on the analysis of cIAP2 in the present study.”
BackgroundRe-Discovery of Pyrimidine Salvage as Target in Cancer Therapy
Walter, M., & Herr, P. (2022) · Cells · doi:10.3390/cells11040739 · Cited by 90
“Whereas FUTP impairs RNA synthesis via its incorporation into mRNA, FdUMP covalently inhibits TS resulting in pyrimidine synthesis disruption and ca cer cell death [20].”
BackgroundCardiac lesions induced by 5-fluorouracil in the rabbit
Tsibiribi, P., Bui-Xuan, C., Bui‐Xuan, B., Lombard‐Bohas, C., Duperret, S., Belkhiria, M., Tabib, A., Maujean, G., Descotes, J., & Timour, Q. (2006) · Human & Experimental Toxicology · doi:10.1191/0960327106ht628oa · Cited by 89
Bwatanglang, I. B., Mohammad, F., Yusof, N. A., Abdullah, J., Alitheen, N. B., Hussein, M. Z., Abu, N., Mohammed, N. E., Nordin, N., Zamberi, N. R., et al. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.07.011 · Cited by 86
Mitchell, L., Espinoza, F. L., Mendoza, D., Kato, Y., Inagaki, A., Hiraoka, K., Kasahara, N., Gruber, H. E., Jolly, D. J., & Robbins, J. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox037 · Cited by 93
Meli, L., Jordan, E. T., Clark, D. S., Linhardt, R. J., & Dordick, J. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.065 · Cited by 87
“incorporating its metabolites into RNA and DNA [35].”
BackgroundInfluentialEldehna, W. M., Almahli, H., Al-Ansary, G. H., Ghabbour, H. A., Aly, M. H., Ismael, O. E., Al‐Dhfyan, A., & Abdel‐Aziz, H. A. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1279155 · Cited by 89
Impact of chemotherapy on gastrointestinal functions and the enteric nervous system
Escalante, J., McQuade, R. M., Stojanovska, V., & Nurgali, K. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.021 · Cited by 94
Mesenchymal stem cells: A new platform for targeting suicide genes in cancer
Tehrani, R. M., Verdi, J., Noureddini, M., Salehi, R., Salarinia, R., Mosallaei, M., Simonian, M., Alani, B., Ghiasi, M. R., Jaafari, M. R., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26094 · Cited by 86
Field, M. S., Kamynina, E., Chon, J., & Stover, P. J. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034441 · Cited by 108
Update on pharmacotherapy for ocular surface squamous neoplasia
Bayyat, G. J. A., Arreaza-Kaufman, D., Venkateswaran, N., Galor, A., & Karp, C. L. (2019) · Eye and Vision · doi:10.1186/s40662-019-0150-5 · Cited by 87
Batista, V. L., da Silva, T. F., de Jesus, L. C. L., Coelho-Rocha, N. D., Barroso, F. A. L., Tavares, L. M., Azevedo, V., Mancha-Agresti, P. D. C., & Drumond, M. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.544490 · Cited by 98
Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy
Mafi, A., Rezaee, M., Hedayati, N., Hogan, S. D., Reiter, R. J., Aarabi, M. H., & Asemi, Z. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01047-x · Cited by 94
“They are naturally cytotoxic and disrupt the normal mechanisms of the cells by injuring the genetic material: DNA and RNA [69].”
BackgroundInfluentialBiomarkers of response to therapy in oesophago-gastric cancer
Fareed, K. R., Kaye, P., Soomro, I. N., Ilyas, M., Martin, S. G., Parsons, S. L., & Madhusudan, S. (2008) · Gut · doi:10.1136/gut.2008.155861 · Cited by 92
Bukkitgar, S. D., & Shetti, N. P. (2016) · ChemistrySelect · doi:10.1002/slct.201600197 · Cited by 90
Vanamala, J., Massey, A. R., Pinnamaneni, S. R., Reddivari, L., & Reardon, K. F. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1344186 · Cited by 107
Fang, X.-J., Jeyakkumar, P., Avula, S. R., Zhou, Q., & Zhou, C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.036 · Cited by 84
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 95
“In the case of 5fluorouracil, resistance has been shown to occur by overexpression of its target, thymidylate synthase [46,47].”
BackgroundCircular CPM promotes chemoresistance of gastric cancer via activating PRKAA2‐mediated autophagy
Fang, L., Lv, J., Xuan, Z., Li, B., Li, Z., He, Z., Li, F., Xu, J., Wang, S., Xia, Y., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.708 · Cited by 85
Metal-organic framework nanoshell structures: Preparation and biomedical applications
Tang, J., Huang, C., Liu, Y., Wang, T., Yu, M., Hao, H., Zeng, W., Huang, W., Wang, J., & Wu, M. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215211 · Cited by 85
Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis
Wagner, T., Brand, P., Heinzel, T., & Krämer, O. H. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.010 · Cited by 91
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 92
FGF signaling facilitates postinjury recovery of mouse hematopoietic system
Zhao, M., Ross, J. T., Itkin, T., Perry, J. M., Venkatraman, A., Haug, J. S., Hembree, M. J., Deng, C.-X., Lapidot, T., He, X. C., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393991 · Cited by 84
Truong, W. T., Su, Y., Gloria, D., Braet, F., & Thordarson, P. (2014) · Biomaterials Science · doi:10.1039/c4bm00244j · Cited by 93
Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo
Zhao, X., & Yu, Y.-T. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1084 · Cited by 94
“It has been widely speculated and in some instances demonstrated that 5FU affects the metabolism of both DNA and RNA (2,4).”
BackgroundCeilley, R. I. (2010) · Journal of Dermatological Treatment · doi:10.3109/09546634.2010.507704 · Cited by 85
“The cytotoxic effect of 5-FU occurs via pathways that adversely affect the normal synthesis and functioning of RNA and DNA (Figure 1) (3).”
BackgroundInfluential
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.